Literature DB >> 7979646

Pharmacokinetic interaction between praziquantel and albendazole in Sudanese men.

M Homeida1, W Leahy, S Copeland, M M Ali, D W Harron.   

Abstract

It has been suggested that praziquantel (40 mg/kg) and albendazole (400 mg) administered together may have a synergistic effect on intestinal parasites. In the present study, the pharmacokinetics of these agents, alone and in combination, were investigated in the presence and absence of food in two groups of Sudanese males. The results indicated that praziquantel pharmacokinetics were not effected by co-administration of albendazole although, in the presence of food, the area under the curve (AUC(0-infinity)) of praziquantel increased 2.6 fold. The AUC(0-infinity) of albendazole sulphoxide (the active metabolite of albendazole) increased 4.5-fold when administered with praziquantel, eight-fold when given with food and 12-fold when given with praziquantel and food. The balance between the therapeutic efficacy of this combination of drugs and its safety profile needs to be studied, especially with regard to albendazole.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7979646     DOI: 10.1080/00034983.1994.11812903

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN: 0003-4983


  11 in total

1.  Bioavailability of praziquantel increases with concomitant administration of food.

Authors:  N Castro; R Medina; J Sotelo; H Jung
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

2.  Albendazole Sulfoxide Plasma Levels and Efficacy of Antiparasitic Treatment in Patients With Parenchymal Neurocysticercosis.

Authors:  Gianfranco Arroyo; Javier A Bustos; Andres G Lescano; Isidro Gonzales; Herbert Saavedra; Silvia Rodriguez; E Javier Pretell; Pierina S Bonato; Vera L Lanchote; Osvaldo M Takayanagui; John Horton; Armando E Gonzalez; Robert H Gilman; Hector H Garcia
Journal:  Clin Infect Dis       Date:  2019-11-13       Impact factor: 9.079

Review 3.  Evaluation of nitazoxanide for the treatment of disseminated cystic echinococcosis: report of five cases and literature review.

Authors:  José A Pérez-Molina; Marta Díaz-Menéndez; José I Gallego; Francesca Norman; Begoña Monge-Maillo; Ana Pérez Ayala; Rogelio López-Vélez
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

4.  Pharmacokinetics of combined treatment with praziquantel and albendazole in neurocysticercosis.

Authors:  Hector H Garcia; Andres G Lescano; Vera L Lanchote; E Javier Pretell; Isidro Gonzales; Javier A Bustos; Osvaldo M Takayanagui; Pierina S Bonato; John Horton; Herbert Saavedra; Armando E Gonzalez; Robert H Gilman
Journal:  Br J Clin Pharmacol       Date:  2011-07       Impact factor: 4.335

5.  Albendazole-praziquantel interaction in healthy volunteers: kinetic disposition, metabolism and enantioselectivity.

Authors:  Renata Monteiro Lima; Maria Augusta Drago Ferreira; Teresa Maria de Jesus Ponte Carvalho; Bruno José Dumêt Fernandes; Osvaldo Massaiti Takayanagui; Hector Hugo Garcia; Eduardo Barbosa Coelho; Vera Lucia Lanchote
Journal:  Br J Clin Pharmacol       Date:  2011-04       Impact factor: 4.335

6.  Enantioselective distribution of albendazole metabolites in cerebrospinal fluid of patients with neurocysticercosis.

Authors:  O M Takayanagui; P S Bonato; S A C Dreossi; V L Lanchote
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

Review 7.  Pharmacokinetic optimisation of the treatment of neurocysticercosis.

Authors:  J Sotelo; H Jung
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

8.  Relative bioavailability of three newly developed albendazole formulations: a randomized crossover study with healthy volunteers.

Authors:  I M Rigter; H G Schipper; R P Koopmans; H J M van Kan; H W Frijlink; P A Kager; H-J Guchelaar
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

Review 9.  A review of pharmacokinetic drug-drug interactions with the anthelmintic medications albendazole and mebendazole.

Authors:  Shane Ashley Pawluk; Craig Allan Roels; Kyle John Wilby; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2015-04       Impact factor: 5.577

Review 10.  Spinal cystic echinococcosis--a systematic analysis and review of the literature: part 2. Treatment, follow-up and outcome.

Authors:  Andreas Neumayr; Francesca Tamarozzi; Sam Goblirsch; Johannes Blum; Enrico Brunetti
Journal:  PLoS Negl Trop Dis       Date:  2013-09-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.